Hundreds of gene and oligonucleotide therapies are in clinical development,9_Gene, cell, & RNA therapy landscape: Q1 2023 quarterly data report_, American Society of Gene & Cell Therapy and Citeline, 2023.;) and several have been approved over the past decade.
Hundreds of gene and oligonucleotide therapies are in clinical development,9_Gene, cell, & RNA therapy landscape: Q1 2023 quarterly data report_, American Society of Gene & Cell Therapy and Citeline, 2023.;) and several have been approved over the past decade. Viral vector gene therapies are now used to treat diseases such as hemophilia B, retinal dystrophy, and spinal muscular atrophy. More recently, mRNA vaccines were pivotal in curbing the spread of COVID-19 and have further accelerated interest in the potential of oligonucleotide-based therapeutics. VC investors provided $3 billion in funding for this group in 2022.